VIDEO: Zeposia meets multiple efficacy endpoints in UC

In this exclusive video, William Sandborn, MD, from the University of California, San Diego, discusses research presented at UEG Week Virtual that explored the safety and efficacy of Zeposia in ulcerative colitis.In the TOUCHSTONE open label extension study, researchers found that Zeposia (ozanimod, Bristol-Myers Squibb) sphingosine-1-phosphate receptor subtype 1 modulator, had durable efficacy in clinical, endoscopic, histologic and biomarker endpoints. Additionally, they identified no new safety risks through 4 years of follow-up.Read More

Share on facebook
Share on twitter
Share on linkedin